文献速递眼底病与葡萄膜炎

阿达木单抗治疗非感染性葡萄膜炎的成本效果分析

Adalimumab for non-infectious uveitis: is it cost-effective?
PubMed 文献 · Br J Ophthalmol · 2019-02-06

该研究基于Markov模型评估阿达木单抗对比当前实践(免疫抑制剂和全身糖皮质激素)治疗非感染性中间、后段或全葡萄膜炎的成本效果,效果数据来自VISUAL I和VISUAL II试验。结论认为阿达木单抗在失明风险较高的活动性葡萄膜炎患者中可能更具成本效果,但需更多原始数据验证。

要点

  • 失明风险高的活动性葡萄膜炎患者可能更具成本效果。

核心结论

  • 阿达木单抗对比有限当前实践的ICER高于英国通常接受的成本效果阈值。
  • 在失明风险较高的活动性葡萄膜炎患者中阿达木单抗可能更具成本效果。
  • 需要更多原始数据以提供更可靠的估计,涉及阿达木单抗对比当前实践的有效性、长期失明发生率、避免失明的有效性以及缓解率和缓解时间。

研究设计与样本

  • 构建Markov模型估计干预措施的成本和收益。
  • 进行系统评价以识别相关临床和成本效果证据。
  • 使用VISUAL I和VISUAL II两项关键随机对照试验的数据估计干预措施对比试验对照臂(安慰剂加有限当前实践)的有效性。
  • 分析从英国国家卫生服务和个人社会服务视角进行,成本基于英国标准来源计算。

临床怎么用

  • 在失明风险较高的活动性葡萄膜炎患者中可考虑阿达木单抗以改善成本效果。
  • 需结合患者具体风险分层评估阿达木单抗的成本效果。

局限性

  • 缺乏阿达木单抗对比当前实践(而非有限当前实践)的有效性数据。
  • 长期失明发生率和阿达木单抗避免失明的有效性数据不足。
  • 阿达木单抗治疗期间的缓解率和缓解时间数据缺乏。
  • 需要更多原始数据以提供更可靠的估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Uveitis is inflammation inside the eye. Our objective was to assess the cost-effectiveness of adalimumab compared with current practice (immunosuppressants and systemic corticosteroids) in patients with non-infectious intermediate, posterior or panuveitis and to identify areas for future research. METHODS: A Markov model was built to estimate costs and benefits of the interventions. Systematic reviews were performed to identify the available relevant clinical and cost-effectiveness evidence. Data collected in two key randomised controlled trials (VISUAL I and VISUAL II) were used to estimate the interventions' effectiveness compared with the trials' comparator arms (placebo plus limited current practice (LCP)). The analysis was performed from the National Health Service and Personal Social Services perspective. Costs were calculated based on standard UK sources. RESULTS: The estimated incremental cost-effectiveness ratios (ICERs) of adalimumab versus LCP for the base case are £92 600 and £318 075 per quality-adjusted life year (QALY) gained for active and inactive uveitis, respectively. In sensitivity analyses, the ICER varied from £15 579 to £120 653 and £35 642 to £800 775 per QALY for active and inactive uveitis. CONCLUSION: The estimated ICERs of adalimumab versus LCP are above generally accepted thresholds for cost-effectiveness in the UK. Adalimumab may be more cost-effective in patients with active uveitis at greater risk of blindness. However, there is an unmet need for additional primary data to provide more reliable estimates in several important areas, including effectiveness of adalimumab versus current practice (instead of LCP), incidence of long-term blindness, adalimumab effectiveness in avoiding blindness, and rates and time to remission while on adalimumab.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Bermejo I, Squires H, Poku EN, et al. Adalimumab for non-infectious uveitis: is it cost-effective? Br J Ophthalmol. 2019. PMID: 30728124. doi:10.1136/bjophthalmol-2018-312756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。